

ondine



For Immediate Release

Ondine Expands MRSA Approvals with MRSAid™ Photodisinfection System

VANCOUVER, BC, April 1, 2009 – Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) a medical technology company developing photodisinfection-based products, today announced that it has received additional Health Canada Licenses for its MRSAid™ Photodisinfection System. The system is designed to reduce Methicillin-resistant *Staphylococcus aureus* (MRSA) colonization of the anterior nasal passages. The nose is a major reservoir of this virulent pathogen and a primary route of transmission for hospital acquired infections.

“MRSA infections can be life-threatening events, placing huge burdens on our healthcare system,” said Carolyn Cross, Ondine’s Chairman & CEO. “Approximately 94,000 life-threatening infections associated with MRSA are reported annually in the US, resulting in more deaths each year than HIV/AIDS. Because these infections do not respond to first-line antibiotic therapy, treatment is often complex, expensive and ineffective. Ondine’s non-antibiotic MRSAid™ system is designed to block carriage of these resistant microbes before transmission can occur between patients, visitors and healthcare workers. The commercialization plan for the MRSAid™ system includes continued in-hospital evaluations on high-level MRSA carriers, development of the US regulatory pathway and establishment of distribution partners.”

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information please contact:

Carolyn Cross
Chairman and
Chief Executive Officer
Ondine Biopharma Corporation
(604) 669-0555
ccross@ondinebiopharma.com

Canaccord Adams Ltd.
Nominated Adviser
Ryan Gaffney
+4420 7050 6500